在接受腹腔透析和葡萄糖皮质体治疗的患者中封装腹腔硬化症
Kensei Taguchi1, Yuta Mitsuishi1, Sakuya Ito1
1Division of Nephrology, Department of Medicine, Kurume University School of Medicine, Japan.
Internal medicine (Tokyo, Japan)
|July 12, 2023
概括
葡萄糖皮质类药物可能掩盖腹膜炎症,这是封装腹膜硬化症 (EPS) 的关键因素,这是腹膜透析的严重并发症. 降低葡萄糖皮质醇剂量可能导致EPS的发展或复发.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 病理学 病理学 病理学
背景情况:
- 封装周周硬化 (EPS) 是周周透析 (PD) 的致命并发症.
- 葡萄糖皮质类药物有时用于PD患者治疗其他疾病.
研究的目的:
- 调查葡萄糖皮质激素在掩盖与EPS相关的腹膜炎症中的潜在作用.
主要方法:
- 一个68岁的男性患者的案例研究,他接受了PD10年.
- 在过渡到血液透析期间进行的腹膜活检.
- 监测与葡萄糖皮质醇剂量相关的组织学变化和EPS发展.
主要成果:
- 6.5毫克葡萄糖皮质类药物的初始活检显示没有纤维素的轻度炎症.
- 当葡萄糖皮质醇剂量减少到2.5毫克时,EPS发生了.
- 每天需要超过5毫克的葡萄糖皮质类药物来预防EPS复发.
结论:
- 葡萄皮质类药物可能会隐藏亚临床腹膜炎症,这是EPS的主要驱动因素.
- 在患有EP风险的PD患者中,仔细监测和管理葡萄糖皮质激素剂量至关重要.
相关概念视频
Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications
44
Peritoneal dialysis (PD) is a medical process that removes waste products and excess fluid from the body using the peritoneal membrane as a natural filter.Peritoneal Dialysis MethodsSeveral methods can be used for peritoneal dialysis, including Acute Intermittent Peritoneal Dialysis, Continuous Ambulatory Peritoneal Dialysis, and Automated Peritoneal Dialysis, also known as Continuous Cyclic Peritoneal Dialysis.Acute Intermittent Peritoneal Dialysis (AIPD) is used for patients with uremic...
44
Peritoneal Dialysis I: Introduction and Procedure
62
Peritoneal dialysis (PD) is a procedure that facilitates the exchange of solutes, waste products, electrolytes, and excess fluid between the blood in the peritoneal capillaries and a dialysis solution introduced into the peritoneal cavity.Principles of Peritoneal Dialysis (PD)Diffusion: Waste products such as urea and electrolytes move from high concentrations in the blood to low concentrations in the dialysate across the peritoneal membrane. This mechanism is driven by the concentration...
62
Peritoneal Dialysis III: Nursing Management
50
Peritoneal dialysis, or PD, utilizes the peritoneal membrane as a filter to eliminate excess fluid and waste products. Effective nursing management is essential for ensuring patient safety, preventing complications, and promoting optimal function of the peritoneal dialysis process.Assessment and MonitoringNurses must thoroughly assess the patient before, during, and after each dialysis session. Regular monitoring includes vital signs, daily weight, fluid intake and output, and laboratory values...
50
Nephrotic Syndrome III : Nursing Management
20
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
20
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
155
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
155
Nephrotic Syndrome I : Introduction
9
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
9


